Optimizing stability during the formulation of therapeutic proteins

Monoclonal antibodies and therapeutic proteins for vaccines require extensive stability characterization during their development phase to improve their probability of successful treatment. We will discuss several case studies that demonstrate how the robust intrinsic fluorescence (nanoDSF) and dynamic light scattering (DLS) data obtained from NanoTemper’s Prometheus instruments helped many groups find better formulations and storage buffers to ultimately expedite the lab to clinic pipeline.

Previous Video
Mischievous membrane proteins (and how to tame them)
Mischievous membrane proteins (and how to tame them)

Are you struggling to tame your mischievous membrane proteins? Find out how NanoTemper can help you to char...

Up next
Multi-parameter formulation development for an HIV-vaccine protein with direct validation of epitope binding integrity and stoichiometry
Multi-parameter formulation development for an HIV-vaccine protein with direct validation of epitope binding integrity and stoichiometry

Have a question about Prometheus?

Contact Specialist